ARS Pharmaceuticals
SPRY
SPRY
187 hedge funds and large institutions have $840M invested in ARS Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 68 increasing their positions, 44 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.43% less ownership
Funds ownership: 86.06% → 84.63% (-1.4%)
43% less capital invested
Capital invested by funds: $1.48B → $840M (-$635M)
88% less funds holding in top 10
Funds holding in top 10: 8 → 1 (-7)
Holders
187
Holding in Top 10
1
Calls
$13.5M
Puts
$7.46M
Top Buyers
| 1 | +$32.2M | |
| 2 | +$16.1M | |
| 3 | +$16M | |
| 4 |
BAMCO Inc
New York
|
+$12.3M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$10.4M |
Top Sellers
| 1 | -$30.2M | |
| 2 | -$25M | |
| 3 | -$23.6M | |
| 4 |
DM
Deerfield Management
New York
|
-$22.3M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$19.2M |
